公告表示，本次注销全资子公司是基于公司优化内部管理结构、提高运营效率的考虑，符合公司经营发 展需要。 北京商报讯(记者郭秀娟王悦彤)12月4日，盖世食品发布公告称，公司全资子公司大连盖世生物技术有 限公司已完成注销登记。该公司成立于2013年3月12日，注册资本为人民币100万元，注册地址为辽宁省 大连市旅顺口区长城街道畅达路320号，法定代表人为盖泉泓，经营范围包括食药用菌栽培所需物质的 生产研发及技术咨询服务；保健食品、发酵制品、饮料、速冻食品、罐头食品、豆制品制造及销售；食 药用菌菌种的培育、销售；水产品、蔬菜、水果和坚果的加工及销售；国内一般贸易；货物、技术进出 口等。 ...

Core Viewpoint - Beijing Sunshine Nuohe Pharmaceutical Research Co., Ltd. plans to deregister its subsidiary Nanjing Nuohexin Pharmaceutical Technology Co., Ltd. to optimize internal management and reduce operational costs [1][2] Group 1: Company Overview - The company is proposing to deregister its controlling subsidiary Nanjing Nuohexin, which is considered a related transaction but does not constitute a major asset restructuring [1][2] - Zhao Lingyang, who held various positions in the company from January 2019 to September 2024 and owns 18% of Nuohexin, is identified as a related party [2][3] Group 2: Financial Information - Nuohexin's total assets as of December 31, 2024, were approximately 10.14 million yuan, up from about 8.74 million yuan in 2023, indicating a growth of approximately 15.98% [4] - The total liabilities of Nuohexin increased from approximately 872,784.84 yuan in 2023 to about 9.19 million yuan in 2024, reflecting a significant rise [4] - Nuohexin reported a total revenue of approximately 7.60 million yuan in 2024, with a net loss of about 6.92 million yuan, compared to a net loss of approximately 3.23 million yuan in 2023 [5] Group 3: Reasons for Deregistration - The decision to deregister Nuohexin is based on the company's development plan and the operational status of the subsidiary, aiming to streamline management and enhance operational efficiency [2][5] - After deregistration, the core business and employees of Nuohexin will be managed by its controlling shareholder, ensuring a smooth transition and protection of employee rights [5] Group 4: Impact of Deregistration - The proposed deregistration is not expected to have a significant impact on the overall business development and profitability of the company, although it will change the scope of the consolidated financial statements [5]